{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T14:04:22Z","timestamp":1751637862678,"version":"3.40.2"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.xphs.2025.01.015","type":"journal-article","created":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T15:53:19Z","timestamp":1737820399000},"page":"1315-1325","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A population pharmacokinetic analysis to evaluate the impact of renal impairment on the pharmacokinetics of iberdomide"],"prefix":"10.1016","volume":"114","author":[{"given":"Ping","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongxia","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongjun","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiming","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.xphs.2025.01.015_bib0001","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1021\/acs.jmedchem.6b01921","article-title":"A cereblon modulator (CC-220) with improved degradation of Ikaros and Aiolos","volume":"61","author":"Matyskiela","year":"2018","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.xphs.2025.01.015_bib0002","doi-asserted-by":"crossref","first-page":"E445","DOI":"10.1136\/lupus-2020-000445","article-title":"Effects of targeting the transcription factors Ikaros and Aiolos on B cell activation and differentiation in systemic lupus erythematosus","volume":"8","author":"Rivellese","year":"2021","journal-title":"Lupus Sci Med"},{"issue":"4","key":"10.1016\/j.xphs.2025.01.015_bib0003","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/s41375-019-0620-8","article-title":"Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN","volume":"34","author":"Bjorklund","year":"2020","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"10.1016\/j.xphs.2025.01.015_bib0004","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1136\/annrheumdis-2021-eular.2181","article-title":"OP0132 Effect of iberdomide on cutaneous manifestations in systemic lupus erythematosus: results of a 24-week, placebo-controlled, phase 2 study","volume":"80","author":"Werth","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"15","key":"10.1016\/j.xphs.2025.01.015_bib0005","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.18632\/oncotarget.27973","article-title":"Developing next generation immunomodulatory drugs and their combinations in multiple myeloma","volume":"12","author":"Thakurta","year":"2021","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.xphs.2025.01.015_bib0006","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1080\/14737140.2020.1828071","article-title":"Current developments in the combination therapy of relapsed\/refractory multiple myeloma","volume":"20","author":"Maples","year":"2020","journal-title":"Expert Rev Anticancer Ther"},{"issue":"16_ Suppl","key":"10.1016\/j.xphs.2025.01.015_bib0007","doi-asserted-by":"crossref","first-page":"E20043","DOI":"10.1200\/JCO.2023.41.16_suppl.e20043","article-title":"A phase I\/II study of carfilzomib, iberdomide (CC-220), and dexamethasone (KID) in patients with newly diagnosed transplant-eligible multiple myeloma","volume":"41","author":"Biran","year":"2023","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.xphs.2025.01.015_bib0008","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood-2020-137743","article-title":"First results of iberdomide (IBER; CC-220) in combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"136","author":"van de Donk","year":"2020","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.xphs.2025.01.015_bib0009","doi-asserted-by":"crossref","first-page":"E822","DOI":"10.1016\/S2352-3026(22)00290-3","article-title":"Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1\/2 trial","volume":"9","author":"Lonial","year":"2022","journal-title":"Lancet Haematol"},{"issue":"5","key":"10.1016\/j.xphs.2025.01.015_bib0010","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/cpdd.869","article-title":"First-in-Human, single- and multiple-ascending-dose studies in healthy subjects to assess pharmacokinetics, pharmacodynamics, and safety\/tolerability of iberdomide, a novel cereblon E3 ligase modulator","volume":"10","author":"Ye","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"2","key":"10.1016\/j.xphs.2025.01.015_bib0011","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00228-020-03004-w","article-title":"Evaluation of iberdomide and cytochrome p450 drug-drug interaction potential in vitro and in a phase 1 study in healthy subjects","volume":"77","author":"Gaudy","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.xphs.2025.01.015_bib0012","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s13318-024-00886-4","article-title":"A phase I, open-label, mass balance study of [14C]-iberdomide in healthy subjects","volume":"49","author":"Cheng","year":"2024","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"1","key":"10.1016\/j.xphs.2025.01.015_bib0013","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/bcp.15498","article-title":"Model-based analysis for the population pharmacokinetics of iberdomide and its major active metabolite in healthy subjects and patients with relapsed and refractory multiple myeloma","volume":"89","author":"Cheng","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"1-2","key":"10.1016\/j.xphs.2025.01.015_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2005.05.010","article-title":"Effects of renal failure on drug transport and metabolism","volume":"109","author":"Sun","year":"2006","journal-title":"Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.xphs.2025.01.015_bib0015","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/clpt.2008.59","article-title":"Emerging evidence of the impact of kidney disease on drug metabolism and transport","volume":"83","author":"Nolin","year":"2008","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.xphs.2025.01.015_bib0016","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1001\/archinte.1990.00040031693017","article-title":"Renal failure in multiple myeloma. Pathogenesis and prognostic implications","volume":"150","author":"Alexanian","year":"1990","journal-title":"Arch Internal Med"},{"issue":"17","key":"10.1016\/j.xphs.2025.01.015_bib0017","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1001\/archinte.158.17.1889","article-title":"Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution","volume":"158","author":"Blad","year":"1998","journal-title":"Arch Internal Med"},{"issue":"1","key":"10.1016\/j.xphs.2025.01.015_bib0018","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"10.1016\/j.xphs.2025.01.015_bib0019","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/10428190601126602","article-title":"Renal failure in multiple myeloma: incidence, correlations, and prognostic significance","volume":"48","author":"Eleutherakis-Papaiakovou","year":"2007","journal-title":"Leuk Lymphoma"},{"year":"2025","series-title":"REVLIMID [lenalidomide] Capsules, for Oral Use [package insert]","key":"10.1016\/j.xphs.2025.01.015_bib0020"},{"year":"2017","series-title":"POMALYST\u00ae (pomalidomide) Capsules, for Oral Use [package insert]","key":"10.1016\/j.xphs.2025.01.015_bib0021"},{"year":"2024","article-title":"Human services, food, drug administration, center for drug evaluation, research (CDER)","series-title":"Guidance for Industry: Pharmacokinetics in Patients with Impaired Renal Function \u2013 Study Design","key":"10.1016\/j.xphs.2025.01.015_bib0022"},{"issue":"3","key":"10.1016\/j.xphs.2025.01.015_bib0023","first-page":"273","article-title":"Update and trends on pharmacokinetic studies in patients with impaired renal function: practical insight into application of the FDA and EMA guidelines","volume":"10","author":"Paglialunga","year":"2017","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.xphs.2025.01.015_bib0024","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1023\/A:1011521819898","article-title":"An identifiability analysis of a parent- metabolite model for ivabradine","volume":"28","author":"Evans","year":"2001","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"3","key":"10.1016\/j.xphs.2025.01.015_bib0025","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1208\/s12248-011-9282-9","article-title":"Development of a complex parent-metabolite joint population pharmacokinetic model","volume":"13","author":"Bertrand","year":"2011","journal-title":"AAPS J"},{"issue":"8","key":"10.1016\/j.xphs.2025.01.015_bib0026","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/jcph.892","article-title":"Parent-metabolite pharmacokinetic modeling and pharmacodynamics of Veliparib (ABT-888), a PARP inhibitor, in patients with BRCA 1\/2\u2013Mutated cancer or PARP-sensitive tumor types","volume":"57","author":"Niu","year":"2017","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.xphs.2025.01.015_bib0027","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1681\/ASN.2006060610","article-title":"Hemodialysis acutely improves hepatic CYP3A4 metabolic activity","volume":"17","author":"Nolin","year":"2006","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.xphs.2025.01.015_bib0028","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/bcp.13873","article-title":"Population pharmacokinetics of lenalidomide in patients with B-cell malignancies","volume":"85","author":"Hughes","year":"2019","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.xphs.2025.01.015_bib0029","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1053\/j.ajkd.2016.10.026","article-title":"Pharmacokinetics of pomalidomide in a patient receiving hemodialysis using a high-cutoff filter","volume":"69","author":"Dao","year":"2017","journal-title":"Am J Kidney Dis"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354925000334?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354925000334?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T22:26:12Z","timestamp":1742682372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354925000334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0022354925000334"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2025.01.015","relation":{},"ISSN":["0022-3549"],"issn-type":[{"type":"print","value":"0022-3549"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A population pharmacokinetic analysis to evaluate the impact of renal impairment on the pharmacokinetics of iberdomide","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2025.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of American Pharmacists Association.","name":"copyright","label":"Copyright"}]}}